UroGen Pharma Ltd. (LON:0XOD)

UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of GBP 731.77 million. The enterprise value is 706.57 million.

Market Cap	731.77M
Enterprise Value	706.57M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.26M
Shares Outstanding	n/a
Shares Change (YoY)	+29.37%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	37.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.64
PB Ratio	-10.74
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.25
EV / Sales	10.15
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.84

Financial Position

The company has a current ratio of 4.14

Current Ratio	4.14
Quick Ratio	3.71
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.03
Interest Coverage	-8.27

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-31.21%
Return on Invested Capital (ROIC)	-93.66%
Return on Capital Employed (ROCE)	-75.99%
Revenue Per Employee	271,875
Profits Per Employee	-447,080
Employee Count	235
Asset Turnover	0.38
Inventory Turnover	1.48

Taxes

In the past 12 months, UroGen Pharma has paid 3.03 million in taxes.

Income Tax	3.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.11% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+35.11%
50-Day Moving Average	17.38
200-Day Moving Average	12.23
Relative Strength Index (RSI)	51.26
Average Volume (20 Days)	2,063

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.03

Income Statement

In the last 12 months, UroGen Pharma had revenue of GBP 68.78 million and -113.11 million in losses. Loss per share was -2.39.

Revenue	68.78M
Gross Profit	60.90M
Operating Income	-89.39M
Pretax Income	-110.08M
Net Income	-113.11M
EBITDA	-89.18M
EBIT	-89.39M
Loss Per Share	-2.39

Balance Sheet

The company has 114.56 million in cash and 93.04 million in debt, giving a net cash position of 24.90 million.

Cash & Cash Equivalents	114.56M
Total Debt	93.04M
Net Cash	24.90M
Net Cash Per Share	n/a
Equity (Book Value)	-68.16M
Book Value Per Share	-1.48
Working Capital	108.99M

Cash Flow

In the last 12 months, operating cash flow was -89.87 million and capital expenditures -289,040, giving a free cash flow of -90.16 million.

Operating Cash Flow	-89.87M
Capital Expenditures	-289,040
Free Cash Flow	-90.16M
FCF Per Share	n/a

Margins

Gross margin is 88.54%, with operating and profit margins of -129.95% and -164.44%.

Gross Margin	88.54%
Operating Margin	-129.95%
Pretax Margin	-160.04%
Profit Margin	-164.44%
EBITDA Margin	-129.65%
EBIT Margin	-129.95%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.37%
Shareholder Yield	n/a
Earnings Yield	-15.46%
FCF Yield	-12.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -5.65 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.65
Piotroski F-Score	1